Gotowe bibliografie tematyczne / Aventis / Artykuły w czasopismach

Artykuły w czasopismach na temat „Aventis”

Kliknij ten link, aby zobaczyć inne rodzaje publikacji na ten temat: Aventis.
Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 20 lutego 2023

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Aventis”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.

1

MULLIN, RICK. "SEEKING AVENTIS". Chemical & Engineering News 82, nr 13 (29.03.2004): 8. http://dx.doi.org/10.1021/cen-v082n013.p008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Bouchie, Aaron J. "Aventis to shed ag". Nature Biotechnology 19, nr 1 (styczeń 2001): 5. http://dx.doi.org/10.1038/83528.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

REISCH, MARC. "AVENTIS PAINTS ROSY FUTURE". Chemical & Engineering News Archive 80, nr 25 (24.06.2002): 16. http://dx.doi.org/10.1021/cen-v080n025.p016.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Bouselli, Anthony. "sanofi-aventis U.S. Award". Microbe Magazine 1, nr 9 (1.09.2006): 432–33. http://dx.doi.org/10.1128/microbe.1.432.1.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

&NA;. "Triamcinolone Acetonide Hydrofluoroalkane Inhalation ??? Aventis". Drugs in R & D 3, nr 2 (2002): 141–42. http://dx.doi.org/10.2165/00126839-200203020-00018.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

J.-M.M. "Sanofi-Aventis Ex-Sanofi-Synthelabo". Revue Française des Laboratoires 2004, nr 366 (październik 2004): 8. http://dx.doi.org/10.1016/s0338-9898(04)80124-0.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

MULLIN, RICK. "AVENTIS, AMGEN INK PRICEY DEALS". Chemical & Engineering News 81, nr 37 (15.09.2003): 6. http://dx.doi.org/10.1021/cen-v081n037.p006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

THAYER, ANN. "Aventis Exiting Its CropScience Business". Chemical & Engineering News 78, nr 47 (20.11.2000): 11–12. http://dx.doi.org/10.1021/cen-v078n047.p011a.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

THAYER, ANN. "AVENTIS, ANDRX IN ANTITRUST SUIT". Chemical & Engineering News 79, nr 21 (21.05.2001): 10. http://dx.doi.org/10.1021/cen-v079n021.p010.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Dorey, Emma. "Genta strikes bumper deal with Aventis". Nature Biotechnology 20, nr 6 (czerwiec 2002): 533–34. http://dx.doi.org/10.1038/nbt0602-533b.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
11

Mitchell, Peter. "Sanofi takeover jeopardizes Aventis biotech deals". Nature Biotechnology 22, nr 6 (czerwiec 2004): 639–40. http://dx.doi.org/10.1038/nbt0604-639.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
12

Fletcher, Liz. "Millennium and Aventis in unique pact". Nature Biotechnology 18, nr 8 (sierpień 2000): 817. http://dx.doi.org/10.1038/78410.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
13

Kühni, Christian, i Björn Christmann. "Corporate real estate management at Aventis". Journal of Corporate Real Estate 6, nr 3 (lipiec 2004): 265–77. http://dx.doi.org/10.1108/14630010410812388.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
14

SHORT, PATRICIA. "SANOFI UPS OFFER TO WIN AVENTIS". Chemical & Engineering News 82, nr 18 (3.05.2004): 8. http://dx.doi.org/10.1021/cen-v082n018.p008.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
15

HILEMAN, BETTE. "Aventis Suspends Bt Corn Seed Sales". Chemical & Engineering News 78, nr 40 (2.10.2000): 13. http://dx.doi.org/10.1021/cen-v078n040.p013.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
16

J.-M. M. "TVP: nouvel anti-Xachez Sanofi-Aventis". Revue Francophone des Laboratoires 2007, nr 389 (luty 2007): 10. http://dx.doi.org/10.1016/s1773-035x(07)80042-6.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
17

THAYER, ANN. "Farmers Sue Aventis Over StarLink Corn". Chemical & Engineering News 78, nr 50 (11.12.2000): 10–11. http://dx.doi.org/10.1021/cen-v078n050.p010.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
18

THAYER, ANN. "Aventis CropScience: Whole Or In Parts?" Chemical & Engineering News Archive 79, nr 13 (26.03.2001): 21. http://dx.doi.org/10.1021/cen-v079n013.p021a.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
19

Moran, Nuala. "Sanofi-aventis snaps up microRNA maker". Nature Biotechnology 28, nr 9 (wrzesień 2010): 880. http://dx.doi.org/10.1038/nbt0910-880.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
20

Hicks, Brian. "Aventis - a new leader in life sciences". Pesticide Outlook 11, nr 3 (2000): 116–18. http://dx.doi.org/10.1039/b006361o.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
21

Kalaria, Raj. "WHO AND AVENTIS TO TACKLE SLEEPING SICKNESS". Neuroreport 12, nr 10 (lipiec 2001): A65—A66. http://dx.doi.org/10.1097/00001756-200107200-00004.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
22

THAYER, ANN. "BAYER IN LEAD FOR AVENTIS AG UNIT". Chemical & Engineering News 79, nr 29 (16.07.2001): 6. http://dx.doi.org/10.1021/cen-v079n029.p006.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
23

LAYMAN, PATRICIA. "Aventis merger marches forward at double time". Chemical & Engineering News 77, nr 21 (24.05.1999): 8. http://dx.doi.org/10.1021/cen-v077n021.p008a.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
24

Ratner, Mark. "Genzyme resumes shipping as Sanofi-aventis hovers". Nature Biotechnology 28, nr 10 (październik 2010): 994. http://dx.doi.org/10.1038/nbt1010-994c.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
25

Hauthal, Hermann G. "Grünes Licht für das Bioindustrie-Unternehmen Aventis". Nachrichten aus Chemie, Technik und Laboratorium 47, nr 10 (październik 1999): 1242–43. http://dx.doi.org/10.1002/nadc.19990471017.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
26

Schmidt, Hartmut. "Unfriendly Takeover". kma - Klinik Management aktuell 9, nr 02 (luty 2004): 10–11. http://dx.doi.org/10.1055/s-0036-1572619.

Pełny tekst źródła
Streszczenie:
Eins plus ein muss größer sein als zwei, nur dann sind Fusionen sinnvoll.Im Falle von Aventis und Sanofi-Synthelabo könnte diese Rechnung aufgehen. Denn Versäumnisse in der Unternehmensführung machen Aventis zur leichten Beute. Die Gewinner und Verlierer stehen auch schon fest.
Style APA, Harvard, Vancouver, ISO itp.
27

&NA;. "Aventis has launched insulin glargine ['Lantus'] in France." Inpharma Weekly &NA;, nr 1403 (wrzesień 2003): 18. http://dx.doi.org/10.2165/00128413-200314030-00037.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
28

Henn, David, i Samuel Amell. "La narrativa de Juan Marse, contador de aventis". Modern Language Review 82, nr 3 (lipiec 1987): 767. http://dx.doi.org/10.2307/3730492.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
29

Bellver, C. G., i Samuel Amell. "La narrativa de Juan Marsé: Contador de aventis". World Literature Today 60, nr 1 (1986): 83. http://dx.doi.org/10.2307/40141172.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
30

Moran, Nuala. "Sanofi Aventis grooms its ranks for biotech partnering". Nature Biotechnology 27, nr 7 (lipiec 2009): 581–82. http://dx.doi.org/10.1038/nbt0709-581.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
31

Leaver, Adam, i Matthieu Montalban. "Sanofi-Aventis and the Complexity of Capitalist Organization". Competition & Change 14, nr 1 (marzec 2010): 1–22. http://dx.doi.org/10.1179/102452910x12587274067999.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
32

Manus, Jean-Marie. "Aventis, nouveau géant franco-européen de l'industrie pharmaceutique". Revue Française des Laboratoires 2000, nr 322 (kwiecień 2000): 8–9. http://dx.doi.org/10.1016/s0338-9898(00)80448-5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
33

Frantz, Simon. "Aventis-Sanofi: a good R&D merger?" Nature Reviews Drug Discovery 3, nr 3 (marzec 2004): 193–94. http://dx.doi.org/10.1038/nrd1358.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
34

 . "1189 Sanofi-Aventis Boekt Winstgroei Van 4,9 Procent". Zorg en Financiering 8, nr 8 (sierpień 2009): 100. http://dx.doi.org/10.1007/bf03098858.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
35

Bengs, Holger. "Die erste SEC-Technology-Tour bei Sanofi-Aventis". Nachrichten aus der Chemie 55, nr 4 (kwiecień 2007): 461. http://dx.doi.org/10.1002/nadc.200749184.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
36

Netting, Jessa. "Aventis gets short shrift over release of modified corn". Nature 408, nr 6811 (listopad 2000): 395. http://dx.doi.org/10.1038/35044248.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
37

J.-M. M. "Sanofi-Aventis + OMS: alliance pour les maladies tropicales négligées". Revue Francophone des Laboratoires 2006, nr 387 (grudzień 2006): 10. http://dx.doi.org/10.1016/s1773-035x(06)80472-7.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
38

Moran, Nuala. "Erratum: Sanofi Aventis grooms its ranks for biotech partnering". Nature Biotechnology 27, nr 10 (październik 2009): 957. http://dx.doi.org/10.1038/nbt1009-957a.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
39

Sandhu, Suneet, Devinder Gill, Paul David Turner, William E. P. Renwick, Maya Latimer, Naomi Mackinlay, Leanne Berkahn i in. "Quality of Life in Fit Elderly Patients with Chronic Lymphocytic Leukemia (CLL) Receiving Oral Fludarabine-Based Regimens As First Line Therapy: Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Trial". Blood 126, nr 23 (3.12.2015): 5295. http://dx.doi.org/10.1182/blood.v126.23.5295.5295.

Pełny tekst źródła
Streszczenie:
Abstract Background The diagnosis and treatment of CLL may have a great impact on the quality of life (QoL) due to a variety of reasons including disease-related symptoms, infection, effects of therapy and the emotional, socio-economic, and functional effects of living with an 'incurable' illness. The main aim of any treatment is to maximize QoL by inducing remission with minimal short- and long-term toxicity. Balancing disease and symptom control with QoL in elderly patients receiving CLL therapy regimens can be challenging. There is little published QoL data in elderly CLL patients receiving the FCR (fludarabine, cyclophosphamide, rituximab) immunochemotherapy regimen. Our prior study showed no significant difference in health related QoL for first-line therapy of CLL with monotherapy between chlorambucil, fludarabine and cladribine (Mulligan, SP et al. Leuk Lymphoma, 2014). Aim We report the QoL assessments of CLL patients enrolled in the ALLG clinical trial CLL5, a randomised, 3-arm, dose de-escalation study of the FCR regimen. Methods The treatment schedule has been described with fit elderly patients randomly assigned to one of three treatment regimens: FR5, FCR3, and FCR5 (Mulligan SP et al. iwCLL Abstract, 2015). Treatment was repeated every 28 days for a planned total of 6 cycles. Importantly, an early stopping rule mandating cessation of therapy was included for any patient having grade 3 or 4 toxicity lasting >2 weeks. QoL assessments using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) were measured at 8 time points: before commencement of therapy, at the end of the 3rd and 6th cycles of treatment, at the final staging and thereafter every 3 months for 12 months. Results Of the 116 evaluable in the study, 2 patients had no QoL data, 6 patients had only baseline QoL data, and 4 patients had no baseline QoL data, therefore the number of patients included in the QoL analysis was 104. There appeared to be a trend towards improved global health (figure 1), physical functioning (figure 2) and role functioning with full dose (FCR5) towards the end of the follow-up period compared to commencement of therapy. Comparison of cognitive functioning (figure 3) between the three arms showed a statistically significant improvement with FCR5. However, on multivariate analysis there was no statistical significant difference. Conclusions Despite a trend favouring full-dose FCR, there were no definitively significant differences in the QoL domains following treatment with FCR-based immunochemotherapy between the three different groups. QoL continues to be a neglected issue, particularly for the typical elderly CLL patient. This study highlights the need for objective QoL assessment as part of all CLL trials, especially those targeted in the typical elderly patient. Figure 1. Mean change from baseline global health status scores with 95% confidence intervals Figure 1. Mean change from baseline global health status scores with 95% confidence intervals Figure 2. Mean change from baseline physical functioning scores with 95% confidence intervals Figure 2. Mean change from baseline physical functioning scores with 95% confidence intervals Figure 3. Mean change from baseline cognitive functioning scores with 95% confidence intervals Figure 3. Mean change from baseline cognitive functioning scores with 95% confidence intervals Disclosures Gill: Roche: Research Funding; Sanofi Aventis: Research Funding; AbbVie: Honoraria; Roche: Honoraria. Turner:Roche: Research Funding; Sanofi Aventis: Research Funding. Renwick:Sanofi Aventis: Research Funding; Roche: Research Funding. Latimer:Sanofi Aventis: Research Funding; Roche: Research Funding. Mackinlay:Sanofi Aventis: Research Funding; Roche: Research Funding. Berkahn:Sanofi Aventis: Research Funding; Roche: Research Funding. Simpson:Janssen-Cilag: Honoraria; Celgene: Honoraria; Onyx Pharmaceuticals: Research Funding; Roche: Honoraria. Forsyth:Sanofi Aventis: Research Funding; Roche: Research Funding. Cull:Janssen-Cilag: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Travel. Harrup:Roche: Research Funding; Sanofi Aventis: Research Funding. Kuss:Sanofi Aventis: Research Funding; Roche: Research Funding. Mulligan:Sanofi Aventis: Research Funding; Janssen: Consultancy, Honoraria, Speakers Bureau; Celgene: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding, Speakers Bureau.
Style APA, Harvard, Vancouver, ISO itp.
40

Amin, Alpesh, Jay Lin, Guiping Yang i Steve Stemkowski. "Clinical and Economic Outcomes Following Full or Partial ACCP Recommended Prophylaxis in Cancer Patients at Risk of Venous Thromboembolism". Blood 112, nr 11 (16.11.2008): 169. http://dx.doi.org/10.1182/blood.v112.11.169.169.

Pełny tekst źródła
Streszczenie:
Abstract Background: As hospitalized cancer patients are at high risk of venous thromboembolism (VTE), evidence-based guidelines recommend VTE prophylaxis in this population. However, although VTE prophylaxis is frequently provided to at-risk medical and surgical cancer patients, it often fails to meet the criteria for best practice recommendations. As few data are available on the impact of inappropriate prophylaxis on clinical outcomes, we compare the safety and efficacy of fully appropriate or partially appropriate VTE prophylaxis in cancer patients using data from a large hospital administrative database. Methods: Discharges from the Premier Perspective database (Jan 02–Dec 06) with a principal diagnosis of cancer, age ≥40 years, length of stay ≥6 days, and receiving some form of VTE prophylaxis, were included in the analysis. Discharges were excluded if they were transferred from another acute care facility or had any contraindications to VTE prophylaxis. Discharges were divided into two groups: full prophylaxis, receiving ACCP-recommended prophylaxis for a sufficient duration (length of stay minus 2 days; minimum 3 days); partial prophylaxis, receiving some form of prophylaxis that was not recommended by the ACCP guidelines, or receiving a guideline-recommended prophylaxis type, but for an insufficient duration. VTE, readmission, bleeding, mortality rates, and total hospital costs were collected and compared between groups using multivariate regression modelling. Results: Among the 83,794 eligible discharges, the full prophylaxis group (n = 13,387, 16%) had a lower in-hospital VTE rate than the partial prophylaxis (n = 70,407, 84%) group (0.8% vs. 2.9%; odds ratio [OR] 3.09, 95% confidence intervals [CI] 2.51–3.80). Similarly, in-hospital mortality rates were lower in the full prophylaxis group (2.6% vs. 4.2%; OR 1.48, 95% CI 1.29–1.69). No major bleeding events were observed in either group, potentially due to the miscoding of these events. The mean total hospital cost was higher for patients receiving partial prophylaxis ($17,128) than full prophylaxis ($15,284). Conclusion: US cancer patients receiving partial prophylaxis have a higher risk of VTE and mortality than patients receiving full guideline-recommended prophylaxis, leading to a higher total hospital cost. It is important that individual hospitals improve the use of full prophylaxis to reduce both the clinical and economic burden posed by VTE. Disclosures: Amin: sanofi-aventis: Consultancy, Financial and editorial support for this publication was provided by sanofi-aventis US, Inc., Honoraria. Lin:sanofi-aventis: Employment. Yang:sanofi-aventis: employee of Premier Inc which has received funding to perform this research from sanofi-aventis. Stemkowski:sanofi-aventis: employee of Premier Inc which has received funding to perform this research from sanofi-aventis.
Style APA, Harvard, Vancouver, ISO itp.
41

Rezende, Pedro Milanez de, i Eudes de Arruda Carvalho. "Avaliação de cultivares de soja [Glycine max (L.) Merrill] para o sul de Minas Gerais". Ciência e Agrotecnologia 31, nr 6 (grudzień 2007): 1616–23. http://dx.doi.org/10.1590/s1413-70542007000600003.

Pełny tekst źródła
Streszczenie:
Visando gerar informações que auxiliem técnicos e produtores na escolha da cultivar a ser utilizada em Lavras e região em plantio de verão, foi desenvolvido o presente trabalho no campo experimental da Universidade Federal de Lavras, no ano agrícola 2002/03, utilizando-se delineamento de blocos casualizados com três repetições e 45 tratamentos, constituídos pelas cultivares: Doko RC, Pioneira, Virtuosa, Conquista, FT-104, Monarca, Monsoy 108, Monsoy 109, FT-Abyara, Performa, Liderança, Monsoy 8400, Confiança, Splendor, UFV-16, Garantia, Renascença, IAC-19, FT-2000, IAC-21, CAC-1, Monsoy 8411, Suprema, Segurança, Aventis 7002, Paiaguás, Carrera, Santa Rosa, BRS - Celeste, DM 339, BRS Carla, BRS Milena, Vencedora, BR-9 Savana, Aventis 2056-7, STTE 02, Aventis 1043, Monsoy 8866, Monsoy 8329, Monsoy 9010, Embrapa 48, Emgopa 313, Emgopa 314, Tucano e BRS 136. As cultivares apresentaram produtividades satisfatórias, com destaque para Vencedora (4.395 kg.ha-1), Paiaguás (3.897 kg.ha-1), Aventis 2056-7 (3.780 kg.ha-1), Monarca (3.646 kg.ha-1) e FT 2000 (3.498 kg.ha-1). Altura da planta e inserção do primeiro legume variaram de 0.68 a 1,53m e de 0.08 a 0.29 m, respectivamente. O índice de acamamento foi satisfatório para todas cultivares testadas. A qualidade da semente foi avaliada através do critério de notas variando de 1 a 2.3 numa escala de 1 a 5.
Style APA, Harvard, Vancouver, ISO itp.
42

Walenga, Jeanine M., Walter Jeske, Debra Hoppensteadt, Josephine Cunanan, Vicki Escalante, Hussein Khan, Joseph Bailey, Jawed Fareed i Mamdouh Bakhos. "Comparative Studies On Branded Enoxaparin and a US Generic Version of Enoxaparin." Blood 120, nr 21 (16.11.2012): 2264. http://dx.doi.org/10.1182/blood.v120.21.2264.2264.

Pełny tekst źródła
Streszczenie:
Abstract Abstract 2264 Background: Low molecular weight heparins (LMWHs) are complex biologic drugs whose heterogeneity in saccharide chain length and in the composition (sulfate, acetyl), content, and location of functional groups can impact their multiple biologic activities. Enoxaparin (Lovenox®) is validated for multiple indications and is the most widely used LMWH in the US. Several generic versions of enoxaparin are currently available in the US. We undertook this study to compare the activity profile of branded and a generic enoxaparin. Methods: Five batches each of branded (B; Sanofi-aventis; Bridgewater, NJ) and generic (G; Sandoz US; Princeton, NJ) enoxaparin were studied. Drugs were purchased through hospital pharmacies as pre-filled syringes containing 40 mg drug. The molecular weight profile of each batch of LMWH was determined using HPLC. To analyze in vitro activities, LMWHs were supplemented to normal human plasma and assessed using amidolytic anti-FXa and anti-FIIa, fibrinokinetic, and thrombin generation assays. Human whole blood was supplemented with LMWHs and the dynamic blood coagulation process was analyzed by thrombelastography (TEG). Whole blood flow cytometry was used to assess the ability of the LMWHs to inhibit tissue factor (TF)-induced platelet activation and lipopolysaccharide (LPS)-induced neutrophil activation. To assess the in vivo effect of the LMWHs, primates treated subcutaneously with a dose of 1 mg/kg LMWH had blood samples drawn pre-treatment and at 4, 6, 12 and 24 hours. Ex vivo pharmacodynamic activities of TFPI release, TAFI inhibition, and thrombin generation inhibition were evaluated. Results: Molecular weight parameters and IC50 values for FXa and FIIa inhibition by branded and generic enoxaparin were comparable. In the in vitro thrombin generation and fibrinokinetic assays, branded enoxaparin exhibited a more potent anticoagulant effect demonstrating slower clot formation with a weaker final clot structure (p=0.01) than generic enoxaparin. Although both the branded and generic enoxaparin produced a concentration-dependent anticoagulant effect in the TEG, there was greater degree of variability for the generic product between blood donors and between batches resulting in a less predictable linear response as drug concentration increased. When the increase in TEG R-time was plotted vs. concentration, branded enoxaparin showed a stronger anticoagulant effect (p=0.05). A concentration-dependent reduction in TF-induced platelet P-selectin expression was observed with branded and generic enoxaparin producing a similar effect. Incubation of whole blood with LPS resulted in a dramatic increase in neutrophil CD11b expression (MFI: 13.1±2.8 vs. 249.0±42.1) which was reduced by increasing concentrations of LMWH. This effect appeared to be stronger for generic than branded enoxaparin (MFI: 165.2±31.9 vs. 208.9±25.9). In primates treated with branded and generic enoxaparin, anti-FXa activity assessed by AUC 0–24hrs was similar. Anti-FIIa activity, however, was significantly higher in primates treated with generic enoxaparin (135±28 vs. 91±20 (μg*hr)/ml; p=0.023). AUC for thrombin generation inhibition was (B) 932±59 vs. (G) 775±119 %inhibition*hr; p=0.029. AUC for TFPI release was (B) 1101±98 vs. (G) 822±13 (ng/*hr)/ml; p=0.006. AUC for inhibition of TAFI activation was (B) 780±73 vs. 906±69 % inhibition*hr; p=0.023. Conclusions: This investigation demonstrated a wider variation in anticoagulant response to generic enoxaparin in comparison to branded enoxaparin. This variation was due to the response of the individual subject as well as to the batch of the product. In addition, both in vitro and in vivo/ex vivo activity differences were observed between branded and generic enoxaparin in several parameters relevant to the antithrombotic effect of LMWH. These findings suggest that simple analytical characterization can establish good quality control in manufacturing but may not assure similarity in biological performance between branded and generic enoxaparin. Thus beside the routinely required characterization, inclusion of additional tests for biologic activities and pharmacodynamic profiling of generic products in animal models may provide useful information on the bioequivalence of the generic versions of enoxaparin. Disclosures: Walenga: Sanofi-Aventis, Paris, France: Research Funding. Jeske:Sanofi-Aventis, Paris, France: Research Funding. Hoppensteadt:Sanofi-Aventis, Paris, France: Research Funding. Cunanan:Sanofi-Aventis, Paris, France: Research Funding. Escalante:Sanofi-Aventis, Paris, France: Research Funding. Khan:Sanofi-Aventis, Paris, France: Research Funding. Bailey:Sanofi-Aventis, Paris, France: Research Funding. Fareed:Sanofi-Aventis, Paris, France: Research Funding. Bakhos:Sanofi-Aventis, Paris, France: Research Funding.
Style APA, Harvard, Vancouver, ISO itp.
43

Amin, Alpesh N., Jay Lin i Daniel Wiederkehr. "Prevention of Deep Vein Thrombosis In Patients In the United States with Infectious Diseases". Blood 116, nr 21 (19.11.2010): 4389. http://dx.doi.org/10.1182/blood.v116.21.4389.4389.

Pełny tekst źródła
Streszczenie:
Abstract Abstract 4389 Background: Hospitalized patients with infectious diseases are at risk of venous thromboembolism (VTE), encompassing both deep-vein thrombosis (DVT) and pulmonary embolism (PE). Our analysis evaluated real-world thromboprophylaxis use and DVT/PE rates in patients with infectious diseases in hospital, and for 30 days post-discharge. Methods: Data were extracted from the US Premier Perspective(tm)-i3 Pharma Informatics linked database for patients with infectious disease (International Classification of Diseases Ninth Revision codes for infectious and parasitic diseases, skin infections, chronic infection, and postoperative infection) who had been admitted January 2005–November 2007. Included patients had at least 6 months’ continuous plan enrollment and were aged ≥ 18 years. Patients with a diagnosis of atrial fibrillation were excluded, as were patients with a hospital stay of 0 days or > 30 days. Results: Of the 5,488 at-risk patients analyzed, 31% received inpatient pharmacological or mechanical DVT prophylaxis, and 3.2% received outpatient pharmacological DVT prophylaxis. Mean ± standard deviation duration of prophylaxis was 1.1 ± 2.4 days for inpatients and 0.8 ± 4.6 days post-discharge, with a total duration of 1.9 ± 5.4 days. DVT/PE occurred in 3.61% of patients during hospitalization, and 0.98% of patients were rehospitalized or treated in the outpatient setting for DVT/PE. Conclusions: Our analysis highlights the considerable rate of DVT/PE and the underuse of DVT prophylaxis in hospitals. Furthermore, DVT/PE risk persisted post-discharge, yet few patients received outpatient prophylaxis. Improved prevention of DVT is required across the continuum of care to reduce preventable mortality and morbidity in patients with infectious diseases. Acknowledgment: this study was funded by sanofi-aventis U.S., Inc. The authors received editorial/writing support in the preparation of this abstract provided by Hester van Lier, PhD of Excerpta Medica, funded by sanofi-aventis U.S., Inc. Disclosures: Amin: sanofi-aventis US Inc.: Honoraria, Speakers Bureau. Lin:sanofi-aventis US Inc.: Employment, Research Funding. Wiederkehr:sanofi-aventis US Inc.: Research Funding.
Style APA, Harvard, Vancouver, ISO itp.
44

Oza, A. M., V. Castonguay, D. Tsoref, I. Diaz–Padilla, K. Karakasis, H. Mackay, S. Welch i in. "Corrigendum: Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective". Current Oncology 18, nr 6 (1.12.2011): 303. http://dx.doi.org/10.3390/curroncol18060003.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
45

&NA;. "Aventis' oral DMARD 'Arava' [leflunomide] has been launched in Japan". Inpharma Weekly &NA;, nr 1405 (wrzesień 2003): 21. http://dx.doi.org/10.2165/00128413-200314050-00055.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
46

JARVIS, LISA. "PHARMACEUTICALS Sanofi-Aventis sets its sights on biotech firm Genzyme". Chemical & Engineering News 88, nr 32 (9.08.2010): 7. http://dx.doi.org/10.1021/cen-v088n032.p007a.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
47

"Aventis". Acta Endoscopica 30, S1 (wrzesień 2000): 295–96. http://dx.doi.org/10.1007/bf03021877.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
48

"Aventis Pharmaceuticals". Annals of Oncology 12, nr 5 (maj 2001): 732–34. http://dx.doi.org/10.1093/oxfordjournals.annonc.a000269.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
49

"Aventis Pharmaceuticals". Annals of Oncology 12, nr 8 (sierpień 2001): 1182. http://dx.doi.org/10.1023/a:1011607620350.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
50

"sanofi aventis". Annals of Oncology 19 (czerwiec 2008): iv266. http://dx.doi.org/10.1093/annonc/mdn274.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany bibliografiami na temat „Aventis” dla innych typów źródeł:
Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii